Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: Modulation of sensitization and utility in a truncated immunotherapy regimen in mice

Molecular Nutrition and Food Research

Volumn 57, Issue 5, 2013, Pages 906-915

  Kulis, Mike ^a   Gorentla, Balachandra ^a   Burks, A Wesley ^a   Zhong, Xiao Ping ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CpG; Food allergy; Mouse model; Peanut allergy; TLR9

Indexed keywords

CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; OLIGODEOXYRIBONUCLEOTIDE; PLANT ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLAXIS; ANIMAL; ARTICLE; BLOOD; C3H MOUSE; CHEMISTRY; DENDRITIC CELL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; PEANUT; PEANUT ALLERGY; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANAPHYLAXIS; ANIMALS; ANTIGENS, PLANT; ARACHIS HYPOGAEA; DENDRITIC CELLS; FEMALE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED C3H; OLIGODEOXYRIBONUCLEOTIDES; PEANUT HYPERSENSITIVITY; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; ARACHIS HYPOGAEA; MUS;

EID: 84876427308     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200410     Document Type: Article

References (41)

1. Burks, A. W., Peanut allergy. Lancet 2008, 371, 1538-1546.
2. Kim, E. H., Bird, J. A., Kulis, M., Laubach, S. et al., Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 2011, 127, 640-646; e1.
3. Blumchen, K., Ulbricht, H., Staden, U., Dobberstein, K. et al., Oral peanut immunotherapy in children with peanut anaphylaxis. J. Allergy Clin. Immunol. 2010, 126, 83-91; e1.
4. Jones, S. M., Pons, L., Roberts, J. L., Scurlock, A. M. et al., Clinical efficacy and immune regulation with peanut oral immunotherapy. J. Allergy Clin. Immunol. 2009, 124, 292-300; e1-97.
5. Varshney, P., Jones, S. M., Scurlock, A. M., Perry, T. T. et al., A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol. 2011, 127, 654-660.
6. Buchanan, A. D., Green, T. D., Jones, S. M., Scurlock, A. M. et al., Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol. 2007, 119, 199-205.
7. Keet, C. A., Frischmeyer-Guerrerio, P. A., Thyagarajan, A., Schroeder, J. T. et al., The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 2012, 129, 448-455; e1-5.
8. Vickery, B. P., Pons, L., Kulis, M., Steele, P. et al., Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann. Allergy Asthma Immunol. 2010, 105, 444-450.
9. Thyagarajan, A., Varshney, P., Jones, S. M., Sicherer, S. et al., Peanut oral immunotherapy is not ready for clinical use. J. Allergy Clin. Immunol. 2010, 126, 31-32.
10. Strid, J., Hourihane, J., Kimber, I., Callard, R. et al., Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin. Exp. Allergy 2005, 35, 757-766.
11. Strid, J., Thomson, M., Hourihane, J., Kimber, I. et al., A novel model of sensitization and oral tolerance to peanut protein. Immunology 2004, 113, 293-303.
12. Shreffler, W. G., Castro, R. R., Kucuk, Z. Y., Charlop-Powers, Z. et al., The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J. Immunol. 2006, 177, 3677-3685.
13. Kean, D. E., Goodridge, H. S., McGuinness, S., Harnett, M. M. et al., Differential polarization of immune responses by plant 2S seed albumins, Ber e 1, and SFA8. J. Immunol. 2006, 177, 1561-1566.
14. Kulis, M., Wan, C. K., Gorentla, B. K., Burks, A. W. et al., Diacylglycerol kinase zeta deficiency in a non-CD4(+) T-cell compartment leads to increased peanut hypersensitivity. J. Allergy Clin. Immunol. 2011, 128, 212-214.
15. Bashir, M. E., Louie, S., Shi, H. N., Nagler-Anderson, C., Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J. Immunol. 2004, 172, 6978-6987.
16. Pochard, P., Vickery, B., Berin, M. C., Grishin, A. et al., Targeting Toll-like receptors on dendritic cells modifies the T(H)2 response to peanut allergens in vitro. J. Allergy Clin. Immunol. 2010, 126, 92-97; e5.
17. Berin, M. C., Zheng, Y., Domaradzki, M., Li, X. M. et al., Role of TLR4 in allergic sensitization to food proteins in mice. Allergy 2006, 61, 64-71.
18. Akdis, C. A., Akdis, M., Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 2011, 127, 18-27; quiz 28-29.
19. Ozdemir, C., Kucuksezer, U. C., Akdis, M., Akdis, C. A., Mechanisms of immunotherapy to wasp and bee venom. Clin. Exp. Allergy 2011, 41, 1226-1234.
20. Strait, R. T., Morris, S. C., Finkelman, F. D., IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J. Clin. Invest. 2006, 116, 833-841.
21. Scadding, G. W., Shamji, M. H., Jacobson, M. R., Lee, D. I. et al., Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy 2010, 40, 598-606.
22. Krieg, A. M., Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5, 471-484.
23. Vollmer, J., Krieg, A. M., Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61, 195-204.
24. Vollmer, J., Weeratna, R., Payette, P., Jurk, M. et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34, 251-262.
25. Zhu, F. G., Kandimalla, E. R., Yu, D., Agrawal, S., Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J. Allergy Clin. Immunol. 2007, 120, 631-637.
26. Adel-Patient, K., Ah-Leung, S., Bernard, H., Durieux-Alexandrenne, C. et al., Oral sensitization to peanut is highly enhanced by application of peanut extracts to intact skin, but is prevented when CpG and cholera toxin are added. Int. Arch. Allergy Immunol. 2007, 143, 10-20.
27. Pons, L., Ponnappan, U., Hall, R. A., Simpson, P. et al., Soy immunotherapy for peanut-allergic mice: modulation of the peanut-allergic response. J. Allergy Clin. Immunol. 2004, 114, 915-921.
28. Li, X. M., Serebrisky, D., Lee, S. Y., Huang, C. K. et al., A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J. Allergy Clin. Immunol. 2000, 106, 150-158.
29. Kulis, M., Pons, L., Burks, A. W., In vivo and T cell cross-reactivity between walnut, cashew and peanut. Int. Arch. Allergy Immunol. 2009, 148, 109-117.
30. Kulis, M., Li, Y., Lane, H., Pons, L. et al., Single-tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts. J. Allergy Clin. Immunol. 2011, 127, 81-88.
31. Trong, H. L., Newlands, G. F., Miller, H. R., Charbonneau, H. et al., Amino acid sequence of a mouse mucosal mast cell protease. Biochemistry 1989, 28, 391-395.
32. Otsu, K., Dreskin, S. C., Peanut allergy: an evolving clinical challenge. Discov. Med. 2011, 12, 319-328.
33. Bock, S. A., Munoz-Furlong, A., Sampson, H. A., Further fatalities caused by anaphylactic reactions to food, 2001-2006. J. Allergy Clin. Immunol. 2007, 119, 1016-1018.
34. Kulis, M., Vickery, B. P., Burks, A. W., Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol. Res. 2011, 49, 216-226.
35. Du Toit, G., Katz, Y., Sasieni, P., Mesher, D. et al., Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J. Allergy Clin. Immunol. 2008, 122, 984-991.
36. Chen, L., Arora, M., Yarlagadda, M., Oriss, T. B. et al., Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J. Immunol. 2006, 177, 2373-2383.
37. Xu, W., Tamura, T., Takatsu, K., CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway. Int. Immunopharmacol. 2008, 8, 351-361.
38. Schmitz, N., Dietmeier, K., Bauer, M., Maudrich, M. et al., Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J. Exp. Med. 2009, 206, 1941-1955.
39. Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., Jacobson, M. R. et al., Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 2004, 172, 3252-3259.
40. Shamji, M. H., Wilcock, L. K., Wachholz, P. A., Dearman, R. J. et al., The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J. Immunol. Methods 2006, 317, 71-79.
41. Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L. et al., Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 2006, 355, 1445-1455.